Yet, amid this gloom, one might spy a glint of possibility-a flicker of light in the dark, like a candle in a storm. Could the whispers of Berkshire’s interest hint at a hidden treasure? Or is this merely a trick of the eye, a mirage conjured by the fevered imagination of investors?
A shutdown occurs when Congress fails to pass necessary legislation that would keep funding certain federal agencies. A shutdown does not stop everything. Mandatory government funding for Social Security, Medicare, and Medicaid benefits will continue, although the agencies that oversee these programs could face furloughs, meaning workers will be forced to take a temporary unpaid leave of absence from their jobs. Once the government is reopened, Congress can pass legislation to give back pay to furloughed workers.
Yet the question remains: Does this oracle of data still hum with the alchemy of worth? Or has the engine sputtered, leaving only a smoldering heap of hubris?
Choosing between them feels akin to deciding whether to invest in a bustling metropolis or a well-managed toll road. Let’s don our pith helmets and venture forth.
The shares, now 5% shy of their zenith, yet scaling fresh peaks in 2025, beckon Wall Street’s acolytes like moths to a flame. But why this fervor? Why this blind, almost devout, allegiance to a ticker symbol? The answer lies not in the sterile arithmetic of earnings reports, but in the darker, unspoken recesses of human ambition.
Growth, it must be said, is a far more seductive philosophy. It promises not just profit, but a sense of momentum-a thrilling ride down a slope littered with IPOs and unicorns. And so, with the solemnity of a man choosing a suit for a funeral, I present what may be the ultimate growth stock to allocate $1,000 toward: Amazon.
Berkshire Hathaway stock has wildly outperformed the market over these past few decades, delivering a total gain of 5,502,284% in per-share market value vs. 39,054% for the S&P 500. Today, Berkshire Hathaway has joined the ranks of the $1 trillion market cap club, and investors everywhere follow Buffett\’s trades and guidance to become more successful investors.
Apparently, it was a combination of factors. First, there were *five* price target raises from analysts. I don’t know, five? Seems a little excessive. It’s like they’re just trying to one-up each other. “I’m raising the target, no, I’m raising the target more!” It’s like a pricing war at the dollar store. But, hey, fine, let’s move on.
And so, as is often the case when a broad market index moves steadily upwards, there are always a few bold performers that steal the show. In September, we saw the usual suspects-companies that, with a little nudge here and there, manage to turn the world upside down. Enter stage left: Warner Brothers Discovery (WBD), AppLovin (APP), and Western Digital (WDC). Let’s take a quick wander through this odd little parade.
The catalyst? A little good news from a recent acquisition: Ambry Genetics, the California-based genetic testing company Tempus picked up back in February. Ambry decided to drop a bombshell with its announcement this week: a major update to its cancer risk assessment platform, the CARE Program. This little tweak integrates breast density data into the Tyrer-Cuzick tool for more accurate breast cancer risk assessments. A move that could mean life or death, depending on which side of the betting table you’re sitting on.